Jacqueline Scanlan - Haemonetics Senior Vice President - Human Resources
| HAE Stock | USD 88.46 2.91 3.40% |
President
Ms. Jacqueline D. Scanlan is Senior Vice President Human Resources of the Company. Ms. Scanlan served as Corporationrationrate Vice President, Human Resources, North America at Novo Nordisk, a global healthcare company specializing in diabetes care, from October 2014 to October 2016. In that role, Ms. Scanlan led all aspects of the organization and people strategy for North America, and served as a key member of the Executive Team. Her responsibilities included organization development as well as change and talent management. Prior to Novo Nordisk, from October 2007 to October 2014, Ms. Scanlan held various human resources leadership roles at Campbell Soup Company, a global producer of prepared and fresh foods and beverages, where she was responsible for HR in the International Business and Corporationrationrate functions, as well as Global Talent Management and Organizational Effectiveness. Earlier in her career, Ms. Scanlan held HR roles at BristolMyers Squibb and DuPont Pharmaceuticals Company and was a consultant at Accenture since 2017.
| Age | 46 |
| Tenure | 7 years |
| Address | 125 Summer Street, Boston, MA, United States, 02110 |
| Phone | 781 848 7100 |
| Web | https://www.haemonetics.com |
Jacqueline Scanlan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jacqueline Scanlan against Haemonetics stock is an integral part of due diligence when investing in Haemonetics. Jacqueline Scanlan insider activity provides valuable insight into whether Haemonetics is net buyers or sellers over its current business cycle. Note, Haemonetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Haemonetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jacqueline Scanlan over a week ago Disposition of 4529 shares by Jacqueline Scanlan of FMC at 59.67 subject to Rule 16b-3 | ||
Jacqueline Scanlan over a month ago Disposition of 5132 shares by Jacqueline Scanlan of FMC at 65.97 subject to Rule 16b-3 |
Haemonetics Management Efficiency
The company has Return on Asset of 0.0588 % which means that on every $100 spent on assets, it made $0.0588 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1397 %, implying that it generated $0.1397 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.5 M, whereas Total Current Assets are forecasted to decline to about 437.2 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Bobby Ghoshal | ResMed Inc | 52 | |
| Lisa Kudlacz | Teleflex Incorporated | N/A | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Christopher Ryan | West Pharmaceutical Services | 63 | |
| Roger Graham | Teleflex Incorporated | N/A | |
| Gael Touya | AptarGroup | 54 | |
| Jim Hollingshead | ResMed Inc | 57 | |
| Praneet Mehrotra | Teleflex Incorporated | N/A | |
| Xiangwei Gong | AptarGroup | 54 | |
| Mario Wijker | Teleflex Incorporated | 52 | |
| Cameron Hicks | Teleflex Incorporated | 59 | |
| Jennifer Schneiders | Hologic | 56 | |
| Karen Boylan | Teleflex Incorporated | 47 | |
| Robert Kuhn | AptarGroup | 62 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Quintin Lai | West Pharmaceutical Services | 53 | |
| Silji Abraham | West Pharmaceutical Services | 52 | |
| Chad Campbell | AngioDynamics | 53 | |
| David Helsel | AngioDynamics | 60 | |
| Ian Bell | Alcon AG | 53 | |
| Kim Seabury | AngioDynamics | 57 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0588 |
Haemonetics Leadership Team
Elected by the shareholders, the Haemonetics' board of directors comprises two types of representatives: Haemonetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haemonetics. The board's role is to monitor Haemonetics' management team and ensure that shareholders' interests are well served. Haemonetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haemonetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stewart Strong, President Hospital | ||
| Rajeev Varma, Senior Development | ||
| William Burke, Chief Financial Officer, Executive Vice President | ||
| Olga Guyette, Director Relations | ||
| Carla Burigatto, VP Communications | ||
| Laurie Miller, Senior Officer | ||
| Ronald Gelbman, Interim CEO, Lead Director, Chairman of Governance and Compliance Committee and Member of Audit Committee | ||
| Robert Abernathy, Independent Director | ||
| Ellen Zane, Non-Executive Independent Chairman of the Board | ||
| Claire Pomeroy, Independent Director | ||
| Michelle Basil, Executive Vice President General Counsel | ||
| Christopher Simon, President, Chief Executive Officer, Director | ||
| Catherine Burzik, Independent Director | ||
| Mark Kroll, Independent Director | ||
| Michelle JD, General VP | ||
| James Darecca, Executive Vice President, Chief Financial Officer | ||
| James CPA, Executive CFO | ||
| Jacqueline Scanlan, Senior Vice President - Human Resources | ||
| Josep Llorens, Senior Vice President - Global Manufacturing and Supply Chain | ||
| Farris Maunsell, Chief VP | ||
| Jan MD, Senior Officer | ||
| Richard Meelia, Non-Executive Independent Chairman of the Board | ||
| Anila Lingamneni, Executive Vice President, Chief Technology Officer | ||
| Francis Tan, Sr Planning | ||
| Charles Dockendorff, Independent Director | ||
| Lloyd Johnson, Director | ||
| Kerri DiPietro, Senior Assurance | ||
| Michael Coyle, Independent Director |
Haemonetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haemonetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0588 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 5.22 B | ||||
| Shares Outstanding | 50.22 M | ||||
| Shares Owned By Insiders | 0.89 % | ||||
| Shares Owned By Institutions | 99.11 % | ||||
| Number Of Shares Shorted | 5.16 M | ||||
| Price To Earning | 50.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.